When ENTA collects another $75M milestone for formal EU approval of Viekirax/Exviera* in January or February (#msg-108396853), ENTA’s cash balance will soar to the $250-300M range without even counting royalties (#msg-108457656).
*The EU brand names for the Viekira Pak constituent drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.